Oncologists near Bronxville, NY

Biography: Dr. Lentzsch is a Professor of Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Irving Medical Center/NewYork-Presbyterian Hospital. She received her medical and doctorate degrees from Humboldt University in Berlin, Germany, where she also completed her residency and fellowship. She did a research fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper Multiple Myeloma Center under the mentorship of Dr. Kenneth Anderson at the Dana-Farber Cancer Institute, Boston, MA, USA. Dr. Lentzsch was recruited in August 2004 to the University of Pittsburgh and University of Pittsburgh Cancer Institute (UPCI), PA, USA, and served as Clinical Director of the Multiple Myeloma Program at UPCI before accepting the position as Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Medical Center. She cares primarily for patients with plasma cell dyscrasia including MGUS, Multiple Myeloma, Amyloidosis, POEMS and Waldenstrom's Macroglobulinemia. Dr. Lentzsch is an internationally recognized expert in the field of Multiple Myeloma and Amyloidosis. She serves as a SWOG Myeloma Committee Member, SWOG Study Coordinator and International Myeloma Foundation "Black Swan Research Initiative" committee member. She is a member of the standing advisory board for the evaluation of Secondary Primary Malignancies associated with IMiDs.

Biography: Dr. William Middlesworth joined the medical staff of Morgan Stanley Children's Hospital of NewYork-Presbyterian/Columbia (MSCHONY), Division of Pediatric Surgery in 1997. He currently serves as director of the Pediatric ECMO Program, and Residency Program Director of the Pediatric Surgical Fellowship. Dr. Middlesworth has founded and leads the Pediatric Thyroid Center and the REACH (Researching Esophageal Atresia for Children's Health) Clinic. A graduate of Dartmouth College, Dr. Middlesworth spent two years in the Genetics Department at the Boston Children's Hospital on work leading to the identification and characterization of the dystrophin gene, important in the pathophysiology of muscular dystrophy. He went on to medical school at Rutgers University, and completed his general surgery training at the University of Maryland Medical System. During residency he spent a year as a surgical research fellow at the Royal Children's Hospital in Melbourne, Australia. His pediatric surgery fellowship was completed at MSCHONY. In addition to the responsibilities listed above, Dr. Middlesworth serves on numerous hospital and university committees focused on Quality and Patient Safety, and is the Quality Chair for Columbia Department of Surgery. He is the Surgeon Champion at the Columbia campus for the National Surgical Quality Improvement Project (NSQIP) of the American College of Surgeons. He chairs a multi-institution collaborative to reduce harm and enhance safety in the peri-operative setting that is sponsored by MCIC Vermont, the member-owned malpractice insurance carrier for Columbia, Cornell, New York Presbyterian Hospital, Johns Hopkins Medicine, University of Rochester Medicine and Yale. Dr. Middlesworth is a fellow of the American College of Surgeons, and the American Academy of Pediatrics. He is a member of numerous professional organizations dedicated to advancing the surgical care of infants and children, including the American Pediatric Surgical Association (APSA), the Eastern Association for the Surgery of Trauma(EAST) and the Extra-corporeal Life Support Organization(ELSO), among others. Dr. Middlesworth has been selected as a Best Doctor in New York Magazine, and a Castle Connolly Top Doctor. He has received recognition for excellence in teaching, and authored numerous papers in important journals including the Journal of Pediatric Surgery, the Journal of Pediatric Hematology and Oncology and Pediatric Critical Care Medicine.

Biography: Meghna S. Trivedi, MD, MS cares for patients diagnosed with breast cancer. Dr. Trivedi received her medical degree from the University of Maryland School of Medicine, and completed her residency at the University of Pennsylvania. She went on to complete her fellowship in hematology/oncology at Columbia University. Dr. Trivedi co-leads the Hereditary Breast and Ovarian Cancer Program, a comprehensive, multi-disciplinary initiative aimed at screening, preventing, diagnosing, and treating hereditary breast and ovarian cancer. This innovative program brings together the resources of a world-renowned academic institution, including cutting-edge genomic testing, clinical trials, and experts in hereditary cancers across different specialties. Dr. Trivedi's research and care expertise also includes cancer genetics and genomics, precision medicine, and chemotherapy induced peripheral neuropathy. She is the principal investigator on several clinical trials, and has authored numerous publications in leading peer-reviewed journals. Dr. Trivedi is a member of the American Society of Clinical Oncologists and SWOG.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Mariam El-Ashmawy, MD PhD is a medical oncologist andtranslational scientist with specialization in the treatment of advanced skincancer and ocular melanoma. Her research investigates the complex geneticlandscape of cancer in order to develop new therapies. In the laboratory, her work has been dedicated to understanding the complex genomic landscape of cancer and developing novel targeted therapeutic strategies. Her ongoing projects include testing novel RAS pathway inhibitors in preclinical models of gastric and esophageal cancer as well as a first-in-human clinical trials for patients with NRAS mutant melanoma.

Biography: Dr. Sathe completed her Residency in Internal Medicine at NYP/Weill Cornell and is a graduate of Rutgers-New Jersey Medical School. She also holds a JD from Columbia Law School. Her research focuses on improving cancer care delivery and reducing disparities in treatment and outcomes.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Biography: Monica Bhatia, MD specializes in the care of children with noncancerous blood disorders who may benefit from bone marrow transplantation, especially sickle cell anemia. She and her colleagues are working to reduce the toxicity (side effects) and complications of this treatment without compromising its effectiveness, and to make it available to more patients. The field of pediatric hematology brings with it many intellectual challenges, and bone marrow transplantation in particular is especially dynamic. Dr. Bhatia has the opportunity to provide care for the sickest children, potentially curing their disease. She builds strong relationships with her patients and their families that last for years. It is inspiring for her to see young patients grow up to lead healthy, productive lives. NewYork-Presbyterian/Morgan Stanley Children's Hospital has a robust program for bone marrow transplantation for sickle cell anemia - the only cure for this disease. Dr. Bhatia and her team have witnessed remarkable results among children who are cured with bone marrow transplantation and spared from the potentially life-threatening complications of sickle cell disease. Yet despite the advances made, only 15 percent of patients with sickle cell disease have a matched sibling bone marrow donor. Therefore, Dr. Bhatia and her team conduct research to evaluate a procedure called "CD34-selected stem cell transplantation" to remove T-cells from donor bone marrow for patients without a matched sibling donor. This approach reduces the risk of graft-versus-host disease (GVHD), a potential complication of bone marrow transplantation in which T-cells from the donor attack the tissue of the recipient. This approach to harnessing stem cells could potentially make bone marrow transplantation a safer, effective option for many patients who are seeking a cure for sickle cell disease. Dr. Bhatia and her colleagues are currently assessing reduced-intensity transplantation, which uses lower doses of chemotherapy to decrease the risk of side effects and long-term complications without lowering the effectiveness of treatment. She is also interested in looking for ways to further improve the quality of life of patients who have had a bone marrow transplant in addition to fertility preservation.

Biography: James H. Garvin, MD, PhD, is a board-certified pediatric hematologist-oncologist who specializes in the care of children and adolescents with brain tumors. He is Principal Investigator at CUMC for the Head Start Program of radiation-sparing intensive chemotherapy for infants and young children with brain tumors. He was principal investigator for a Children's Oncolgy Group protocol for childhood ependymoma. He also offers novel therapies for recurrent brain tumors through our program's membership in Developmental Therapeutics Program of the COG. In addition, Dr. Garvin started the pediatric bone marrow transplant program, and continues as a member of the BMT group. He has particular interest in autologous transplant for brain tumors and allogeneic transplant for metabolic disorders and bone marrow failure syndromes, as well as supportive care for BMT patients. Dr. Garvin became interested in pediatric hematology/oncology through research during medical school in the laboratory of a pediatric hematologist. He is a member of numerous professional societies in the field.

Biography: Dr. Andrew H. Lipsky is an Assistant Professor of Medicine at the Columbia University Medical Center. He specializes in caring for adult patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL) and lymphoma.Dr. Lipsky's research focuses on cancer genomics and new treatments for CLL. He has a special interest in using the latest bioinformatics techniques to study how cancer cells change and adapt during treatment. Utilizing these genomic insights, he hopes to better inform clinical trials and hasten the development of innovative therapies for patients with hematologic malignancies.Dr. Lipsky earned his medical degree from Rutgers - Robert Wood Johnson Medical School. He completed internship and residency in internal medicine at Montefiore - Albert Einstein College of Medicine. He completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital Weill Cornell Medical College, with an additional sub-fellowship in the clinical care of CLL and lymphoma. He also completed a postdoctoral research fellowship in lymphoma genomics and bioinformatics as part of the Molecular and Translation Oncology Research (MTOR) training program.

Biography: Manuela Orjuela-Grimm is a molecular epidemiologist and pediatric oncologist whose research focuses on vulnerability (including social) to environmental exposures, gene-nutrient/ environment interactions during windows of susceptibility such as pregnancy, early childhood, adolescence and the development of later genetic and epigenetic changes contributing to poorer health outcomes in childhood and adolescence. She leads EpiRbMx, a long-standing case control/ case series study examining exposure to methyl donors, folate pathway metabolism and risk for retinoblastoma in collaboration with a multidisciplinary team of investigators including the Hospital Infantil de Mexico, the Hospital de Pediatria at the Instituto Mexicano de Seguro Social (IMSS), the Instituto Nacional de Salud Publica (INSP), and the University of Toronto. In collaboration with INSP researchers, Dr. Orjuela is involved in multiple studies examining the intersection between food security, folate-related dietary intake, dietary diversity and environmental exposures in central Mexico, and in immigrants in New York. Interests: social contributors to dietary exposures, gene-nutrient interactions; one carbon donor metabolism; methylation; nutrient and environmental exposures during early life and later genetic and epigenetic effects; dietary assessment in Mexico, in populations on the move in Latin America; effects of acculturation and early life migration on nutrient/ environmental exposures in US Latinos.

Biography: Linda Wu, MD is an Assistant Professor of Medicine at Columbia University Irving Medical Center. Dr. Wu earned her MD degree from Weill Cornell Medical College and completed residency training in Internal Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. She then completed fellowship training in Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai. As a medical oncologist, she specializes in the treatment of gastrointestinal malignancies, with particular focus on pancreatic and hepatobiliary cancers. Dr. Wu is actively involved in research to improve treatments for cancer. She is involved in developing and leading clinical trials, including multicenter investigator-initiated trials, to investigate novel therapeutic strategies for pancreatic and biliary cancers as well as other gastrointestinal malignancies. Her research interests also include discovering biomarkers predictive of response and resistance to therapy and understanding the tumor microenvironment to improve the effectiveness of immunotherapy for gastrointestinal malignancies, and she has published multiple articles in these areas. Dr. Wu works closely as part of a multidisciplinary team to deliver compassionate care at the highest levels, utilizing a personalized approach to offer cutting-edge therapies.

Biography: Aya Haggiagi, MD is an assistant professor of neurology at CUIMC, in the Division of Neuro-Oncology. Dr. Haggiagi is board certified in Neurology and Neuro-Oncology. She graduated with highest honors from the University of Al-Fateh School of Medicine in Tripoli, Libya. She subsequently completed a postdoctoral research fellowship in the Department of Pathology and Cell Biology at Columbia, under the mentorship of Dr. Michael Shelanski, where her research focused on biochemical and genetic changes in neurofibrillary tangle predominant dementia. Dr. Haggiagi then pursued her medicine internship training at Westchester Medical Center, followed by neurology residency at NewYork-Presbyterian/Columbia University Irving Medical Center. After residency, she completed a two-year fellowship in Neuro-Oncology at Memorial Sloan Kettering Cancer Center. Dr. Haggiagi was an attending physician and an investigator at Memorial Sloan Kettering Cancer Center prior to returning to NYP/CUIMC. She is the recipient of the Society for Neuro-Oncology 2017 Best Abstract Award. Her research interests include the development of clinical trials, precision medicine, and neurologic complications of immunotherapy.

Biography: Dr. Stein is an Associate Professor of Medical Oncology at Columbia University Medical Center. He is a recognized expert in field of genitourinary oncology treating patients with prostate, kidney, bladder and testicular cancers. He is also a member of the Experimental Therapeutics program, investigating novel therapies across all solid tumors. In addition to providing standard therapies for the treatment of genitourinary cancers such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator initiated and industry sponsored clinical trials. Dr. Stein has a particular interest in the development of novel immune therapies for the treatment of prostate cancer, both in men with early recurrence of prostate cancer as well as in men with more advanced prostate cancer. He is also helping to lead two national trials in kidney cancer sponsored by the National Cancer Institute. Dr. Stein received his B.S. in Molecular Biophysics and Biochemistry from Yale University. He earned his medical degree at New York Medical College, receiving the graduation award in oncology for his published research. He completed a residency in internal medicine at Montefiore Medical Center, and a fellowship in Hematology and Medical Oncology at Mount Sinai Medical Center. Prior to joining Columbia University, Dr. Stein practiced genitourinary oncology for 13 years at Rutgers University and has been an author on over 60 publications including guidelines for assessing the efficacy of new drugs in prostate cancer and recommendations for the use of immunotherapy to treat prostate cancer.